JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals (Q35005863)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals |
scientific article |
Statements
1 reference
JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals (English)
1 reference
Susan Morgello
1 reference
Kathryn Anastos
1 reference
Joan W Berman
1 reference
24 November 2014
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference